TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14963058
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein diet (at least 20 g) and isoflavones (at least 80 mg) for 5 weeks
Study: 11758227
Drug: Lupus anticoagulant
Normalized name: Lupus anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupus anticoagulant (LA) IgG from SLE patients
Study: 9412880
Drug: Aprotinin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (2 x 10(6) kallikrein inhibitor units in CPB prime)
Study: 3085551
Drug: nalbuphine (0.21
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine (0.21 mg/kg, intravenous)
Study: 3085551
Drug: naloxone (0.014
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone (0.014 mg/kg, intravenous)
Study: 31246234
Drug: Abiraterone acetate,
Normalized name: abiraterone acetate, submicronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone acetate, 1000 mg, once daily with prednisone, 5 mg, twice daily
Study: 31246234
Drug: Abiraterone acetate,
Normalized name: abiraterone acetate, submicronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone acetate, 1000 mg, once daily with prednisone, 5 mg, once daily
Study: 31246234
Drug: Abiraterone acetate,
Normalized name: abiraterone acetate, submicronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone acetate, 1000 mg, once daily with prednisone, 2.5 mg, twice daily
Study: 31246234
Drug: Abiraterone acetate,
Normalized name: abiraterone acetate, submicronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone acetate, 1000 mg, once daily with dexamethasone, 0.5 mg, once daily
Study: 26894653
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg febuxostat twice daily
Study: 26894653
Drug: 40/80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40/80 mg febuxostat once daily
Study: 15640324
Drug: Oral L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-arginine supplementation (200 mg x kg(‐1) body weight, t.i.d. for 6 weeks)
Study: 15640324
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral L-arginine (200 mg x kg(‐1) body weight)
Study: 1369702
Drug: Nicardipine 30
Normalized name: niCARdipine 30 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 30 mg t.i.d. for 2 weeks
Study: 36817
Drug: Cimetidine, 300
Normalized name: Cimetidine, 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 300 mg IV, 2 hr before induction of anesthesia
Study: 36817
Drug: Glycopyrrolate, 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate, 0.3 mg IM, 1 hr before induction of anesthesia
Study: 16540851
Drug: Caffeine 10
Normalized name: caffeine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 10 mg x kg(‐1) body weight
Study: 16540851
Drug: Caffeine 5
Normalized name: caffeine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 5 mg x kg(‐1) body weight
Study: 11680666
Drug: Losartan +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan + Diuretic (L+D)
Study: 11680666
Drug: Calcium Channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Channel Blocker + Diuretic (N+D)
Study: 9270666
Drug: Propionyl-L-carnitine (PLC)
Normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine (PLC) (1.5 g i.v. followed by infusion of 1 mg/kg/min for 30 min, n = 10)
Study: 9270666
Drug: L-carnitine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (1 g i.v. followed by infusion of 0.65 mg/kg/min for 30 min, n = 6)
Study: 8197037
Drug: Ceftizoxime 1
Normalized name: ceftizoxime 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime 1 g plus metronidazole 500 mg intravenously every 12 hours
Study: 8197037
Drug: Cefoxitin 2
Normalized name: cefoxitin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin 2 g intravenously every 6 hours
Study: 8197037
Drug: Ampicillin-sulbactam 3
Normalized name: ampicillin / sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam 3 g every 6 hours
Study: 30975219
Drug: Synergy drug-eluting
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synergy drug-eluting stent (DES)
Study: 30430875
Drug: Combination topical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination topical gel of nifedipine (NIF), lidocaine hydrochloride (LDH), and betamethasone valerate (BMV)
Study: 30430875
Drug: Market products
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Market products (single drug treatments)
Study: 27435332
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg intravenous tranexamic acid (TXA)
Study: 22538054
Drug: Budesonide (3mg)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (3mg) infused locally in the proximal jejunum after administering ketoconazole (doses ranging from 1-128 mg, with an oral dose of 200mg given 12h earlier)
Study: 22538054
Drug: Ketoconazole (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (up to 16 mg)
Study: 22538054
Drug: Ketoconazole (64
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (64 mg and above)
Study: 22538054
Drug: Ketoconazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (1 mg in mucosa and 50 mg in liver)
Study: 22538054
Drug: Budesonide (0.2mg)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (0.2mg) administered intravenously
Study: 19640853
Drug: Onercept 50
Normalized name: Onercept
DrugBank: Onercept (DB06495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onercept 50 mg and 100 mg
Study: 18545216
Drug: Intranasal heating
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal heating and humidification in elderly subjects
Study: 9329640
Drug: Blood cells
Normalized name: Red blood cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood cells of patients subjected to radioiodine therapy
Study: 24955450
Drug: Esomeprazole and
Normalized name: Esomeprazole and naproxen only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole and flupentixol/melitracen (combination therapy)
Study: 24955450
Drug: Esomeprazole only
Normalized name: Esomeprazole only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole only (monotherapy)
Study: 23372114
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with darunavir/ritonavir + 2 NRTIs
Study: 14520123
Drug: Mirtazapine 30
Normalized name: mirtazapine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 30 mg/d
Study: 10926339
Drug: 800 microg
Normalized name: Fentanyl 800 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 microg inhaled budesonide per day
Study: 10926339
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg inhaled budesonide per day
Study: 4017661
Drug: Albumin group
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin group (ALB) received 80 g albumin on the day of operation and 20 g albumin for the following three days.
Study: 24331842
Drug: Milrinone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (50 μg/kg/min loading dose followed by 0.6 μg/kg/min continuous infusion)
Study: 22251615
Drug: Tibolone, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone, 2.5 mg daily
Study: 12595513
Drug: Steroid withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid withdrawal (n = 5)
Study: 12595513
Drug: CsA discontinuation/reduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA discontinuation/reduction (n = 13)
Study: 12595513
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (n = 12)
Study: 12595513
Drug: Lowering CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowering CsA to low target trough (30 to 70 ng/ml)
Study: 11039423
Drug: Membrane differential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Membrane differential filtration treatment, administered five times over a period of 21 weeks.
Study: 11039423
Drug: Membrane differential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Membrane differential filtration treatment.
Study: 9020990
Drug: Pirlindole (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirlindole (300 mg/day)
Study: 2864741
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g sulphasalazine daily
Study: 2864741
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg penicillamine daily
Study: 25887355
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (HbA1c goal < 6%)
Study: 25887355
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (HbA1c goal 7.0% to 7.9%)
Study: 21438849
Drug: Tipranavir/ritonavir (TPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipranavir/ritonavir (TPV/r) 500 mg/200 mg
Study: 19568175
Drug: Nevirapine (NVP)
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine (NVP) administration to women who tested positive for HIV
Study: 19568175
Drug: Inert (calcium)
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert (calcium) tablet provided to women who tested negative for HIV
Study: 1585511
Drug: CisCA chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CisCA chemotherapy
Study: 27704507
Drug: 10 IU
Normalized name: Thyrotropin 10 IU Injection Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 IU bolus of Oxytocin + 25 IU IVD in 500 ml of serum over 3 hours
Study: 27704507
Drug: 5 IU
Normalized name: Vitamin E 15 IU/0.3 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IU IVD of Oxytocin + 25 IU in 500 ml serum over 3 hours
Study: 24667132
Drug: Se-enriched rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se-enriched rice (80 g daily)
Study: 24667132
Drug: Regular rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular rice (80 g daily)
Study: 22521214
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 100/325 mg for 7 days
Study: 20400201
Drug: Gefitinib 250mg
Normalized name: GEFITINIB 250MG TAB
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib 250mg daily
Study: 15876903
Drug: H. perforatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. perforatum (900-1500 mg/d)
Study: 15876903
Drug: Sertraline (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50-100 mg/d)
Study: 12830007
Drug: Octreotide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide infusion (50 microg/h)
Study: 11291022
Drug: Treatment approaches
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment approaches to memory loss, typically using Alzheimer's dementia as the template.
Study: 8676532
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) continuously throughout the postoperative period
Study: 8676532
Drug: Saline as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline as postoperative fluid therapy
Study: 31026086
Drug: Epidural oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural oxycodone 0.1 mg kg‐1 and intravenous saline (EPI-group n = 31)
Study: 31026086
Drug: Intravenous oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxycodone 0.1 mg kg‐1 and epidural saline (IV-group n = 29)
Study: 27111084
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with memantine
Study: 20978525
Drug: Betaine supplementation
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaine supplementation (4 g/day)
Study: 20978525
Drug: Placebo (mineral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mineral water 500 ml/day without betaine)
Study: 20158691
Drug: Ibandronate 2
Normalized name: ibandronate 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 2 mg every 3 months intravenously for 1 year, along with calcium (1 g/day) and vitamin D3 (800-1000 IE/day)
Study: 20158691
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving calcium (1 g/day) and vitamin D3 (800-1000 IE/day)
Study: 8600589
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated varicella vaccine (Oka strain) with a mean virus titre of 10(4,5) PFUs per dose
Study: 8600589
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated varicella vaccine (Oka strain) with a mean virus titre of 10(3,1) PFUs per dose
Study: 8600589
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated varicella vaccine (Oka strain) with a mean virus titre of 10(3,9) PFUs per dose
Study: 8600589
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated varicella vaccine (Oka strain) with a mean virus titre of 10(2,7) PFUs per dose
Study: 8600589
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated varicella vaccine (Oka strain)
Study: 361345
Drug: Loxapine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxapine (average maximum daily dose: 60.0 mg)
Study: 361345
Drug: Perphenazine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine (average daily dosage: 36.8 mg)
Study: 361345
Drug: Loxapine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxapine (average daily dosage: 81.1 mg)
Study: 361345
Drug: Perphenazine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine (average daily dosage: 90.1 mg)
Study: 27995369
Drug: Oral analgesics
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral analgesics (paracetamol, ibuprofen, or a combination)
Study: 11206598
Drug: Once-weekly fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly fluoxetine
Study: 11206598
Drug: Once-daily fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily fluoxetine
Study: 3705820
Drug: Tranquilizers, antidepressants,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranquilizers, antidepressants, neuroleptics, nootropic drugs, and rational psychotherapy
Study: 27367877
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (n=143) provided by primary care physician including periodic contacts, referrals to specialists, and prescription of medication.
Study: 18541128
Drug: Test formulation:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation: ibuprofen (400 mg capsule)
Study: 12135217
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion hysterosonography
Study: 10374704
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus aspirin (single therapy)
Study: 10374704
Drug: Complete therapy
Normalized name: Monistat 7 Complete Therapy Combination Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete therapy (lymphocyte immunizations, heparin, and aspirin)
Study: 7487614
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics (ceftazidime and amikacin)
Study: 2299370
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine (LD ARA‐C) 20 mg/m2 for 21 days
Study: 2299370
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (rubidazone 100 mg/m2 for 4 days, ARA‐C 200 mg/m2 for 7 days)
Study: 29159870
Drug: Predictive low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive low glucose suspension (PLGS) alone
Study: 26619790
Drug: Yogurt with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt with 6 g inulin (YI)
Study: 11836166
Drug: Slow response
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow response to therapy (assessed by percentage of blast cells higher than 10% in bone marrow study on day 14)
Study: 11836166
Drug: Slow response
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow response to therapy (assessed by presence of blast cells in peripheral blood on day 8)
Study: 1986564
Drug: Isocaloric 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric 0.8 g/kg protein diet
Study: 29878445
Drug: Supervised resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised resistance training twice-a-week for 9 months
Study: 16000281
Drug: 18F‐FCWAY (5‐HT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F‐FCWAY (5‐HT 1A receptor antagonist)
Study: 10621951
Drug: Sumatriptan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (100 mg orally)
Study: 10621951
Drug: Subsequent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent treatment with serotonin specific reuptake inhibitors (SSRIs)
Study: 7860745
Drug: 600 mg/d
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/d cholesterol with high saturated fat
Study: 7860745
Drug: 600 mg/d
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/d cholesterol with increased polyunsaturated fat
Study: 7860745
Drug: 200 mg/d
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d cholesterol with high saturated fat
Study: 7860745
Drug: 200 mg/d
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d cholesterol with low saturated fat
Study: 7860745
Drug: 600 mg/d
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/d cholesterol with low saturated fat
Study: 1955161
Drug: Adrenaline injection
Normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenaline injection + Nd:YAG laser photocoagulation
Study: 6135908
Drug: ICI 118630
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118630 (100 micrograms daily)
Study: 6135908
Drug: ICI 118630
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118630 (250 micrograms daily)
Study: 24393134
Drug: UMEC 125
Normalized name: Umecta
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC 125 μg QD
Study: 24393134
Drug: Other UMEC
Normalized name: Umecta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other UMEC doses (15.6, 31.25, 62.5 μg)
Study: 21978210
Drug: Daily aphasia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily aphasia therapy
Study: 21978210
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care therapy
Study: 17457705
Drug: Tramadol as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol as PCA with an infusion of 0.3 mg/kg following a loading dose of 1.5 mg/kg administered 1 hour before the end of the surgery
Study: 17457705
Drug: Ondansetron 0.1
Normalized name: ONDANSETRON 0.16MG/ML D5W INJ BAG 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.1 mg/kg following induction of anesthesia
Study: 17457705
Drug: Morphine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine as PCA with an infusion following a loading dose of 0.15 mg/kg administered 30 minutes before the end of surgery
Study: 17720075
Drug: Ophthalmic review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic review 2 hours after surgery and 2 weeks postoperatively (Group 1)
Study: 17720075
Drug: No ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ophthalmic review before the 2-week postoperative visit (Group 2)
Study: 15003298
Drug: Enoxaparin 20mg
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 20mg subcutaneous injection once daily for 3 weeks
Study: 9543364
Drug: Methylprednisone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisone (5 mg/kg per day in four oral doses over 7 days)
Study: 3291099
Drug: Timegadine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timegadine 500 mg/day
Study: 28485008
Drug: L-carnosine as
Normalized name: L-Carnosine
DrugBank: Carnosine (DB11695)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnosine as adjuvant to fluvoxamine
Study: 25212871
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg for the first day, 75 mg/day thereafter) plus aspirin (100 mg/day)
Study: 25212871
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (300 mg/day)
Study: 24377217
Drug: Jin's three-needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jin's three-needle therapy
Study: 24377217
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (acupuncture and rehabilitation)
Study: 24377217
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Jin's three-needle, rehabilitation, combined therapy)
Study: 11246353
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L of PEG‐ELS with 20 mg bisacodyl
Study: 11246353
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L of PEG‐ELS preceded by 296 mL of magnesium citrate
Study: 11246353
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L of PEG‐ELS
Study: 9141518
Drug: MK-386 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-386 0.1 mg
Study: 9141518
Drug: MK-386 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-386 0.5 mg
Study: 9141518
Drug: MK-386 5
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-386 5 mg
Study: 9141518
Drug: MK-386 20
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-386 20 mg